Slides
Page 1
Q2 2026 Earnings Deck August 6th , 2026 Cryoport Enabling the Future of Medicine
Page 2
2© 2026 CRYOPORT, INC. Forward-Looking Statements Statements in this press release which are not purely historical, including statements regarding the Company's intentions, ho pes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financia l condition, such as the Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Com pany’s expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expan sions or moves to earlier lines of treatment approved with respect to the products of the Company's clients. Forward -looking statements also include those related to the Company’s plans regarding its Global Supply Chain Centers, including expected timing of future openings, the C ompany’s anticipation that it will benefit from its operating leverage, the Company’s belief that it is well positioned to further exp and margins, enhance operating efficiency and deliver sustainable, profitable long-term growth for its shareholders, and the Company’s expectation th at upcoming growth catalysts in its business segments will drive the Company to new heights in market position, growth, and productivity. It is important to note that the Company's actual results could differ materially from those in any such forward -looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect s of changing economic and geopolitical conditions, such as those resulting from the war with Iran, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in the Company’s cash flow, market accep tance risks, the effects of tariffs and other trade restrictions, and technical development risks. The Company's business could be affected by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports o n Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release spe ak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward -looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward -looking statements in this press release. Forward Looking Statements 2
Page 3
3© 2026 CRYOPORT, INC. Life sciences company focused on providing mission critical, proprietary temperature-controlled supply chain solutions Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature-controlled state such as: – Cell therapies – Gene therapies – Human and animal reproductive materials The recognized supply chain leader in supporting the C> market The leading manufacturer of cryogenic systems and accessories in the world One of the largest biorepositories in the U.S. Cryoport, Inc. (CYRX) operates as an operating holding company with a family of businesses that have separate responsibilities but collectively provide synergistic solutions to the life sciences industry Cryoport – Trusted Partner to Life Sciences Companies
Page 4
4© 2026 CRYOPORT, INC. Cryoport Snapshot – By the Numbers Leading integrated platform ensuring the integrity of critical biomaterials across the life sciences value chain Note: Number of active CGT clinical trials and commercial CGTs supported as of June 30, 2026. 779 Active CGT Clinical Trials $49M +8% Organic Growth Q2 FY2026 Revenue 25% Q2 BioStorage/BioServices Growth YoY 46.6% Q2 FY2026 Gross Margin $0.4M $1.3M Improvement YoY Q2 FY2026 Adjusted EBITDA 22 Commercial CGTs Supported $192-$196M +9-11% Organic Growth FY2026 Updated Revenue Guidance $397M Q2 FY2026 Cash ($185M senior convertible debt to be repaid 12/2026)
Page 5
5© 2026 CRYOPORT, INC. Revenue from supporting Commercial Cell and Gene Therapies Q1 2024 through Q2 2026
Page 6
6© 2026 CRYOPORT, INC. Q2 Life Sciences Services Overview
Page 7
7© 2026 CRYOPORT, INC. Q2 FY2026 Revenue Strong Growth Across All Services +8% Total revenue (Year over Year) +15% +25% +26% Life Sciences Services Revenue BioServices & Biostorage Revenue Commercial Cell & Gene Therapy Services Revenue Q2 2026 Revenue Drivers Strong double-digit growth across the platform of services
Page 8
8© 2026 CRYOPORT, INC. Cell Therapy Market Growing 28% Through 2030 (Includes Cell and CAR-T Therapies)
Page 9
9© 2026 CRYOPORT, INC. CGT Industry Funding ($ bil.)
Page 10
10© 2026 CRYOPORT, INC. Growth in U.S. CGT Claims and Treatment Centers (2018 vs. 2025) Source: Alliance for Regenerative Medicine Whitepaper - Cell & Gene Therapy Expansion: The Evolution of CGT Delivery in the U.S. – June 2026
Page 11
11© 2026 CRYOPORT, INC. Patients First: Supporting the Therapies of Tomorrow Clinical Trials Supported, by Trial Phase CGT Industry Market Share1 Forecasted BLA / MAA Filings & Patient Population Growth Currently forecasts up to 14 possible BLA / MAA filings and 9 approvals in 2026, with the majority being for new therapies Industry experts anticipate 30 - 50 additional CGT approvals by 2030 The patient population for CGTs is projected to grow significantly as more treatments are approved The Company continues to introduce capabilities to its existing clients and adds new clients to its global network Remains focused on scaling its services to meet the needs of the patient population growth 22 Commercial Therapies Supported AKUUGO® ® 255 275 282 299 313 318 273 300 311 321 361 357 74 79 82 81 86 91 2021 2022 2023 2024 2025 Q1 2026 602 654 675 701 760 Phase I Phase II Phase III Others ~30% Cryoport~ 70% Total Number of Clinical Trials ~ 1,100 1Source: Company materials cross-referenced to clinical trial information publicly available 766 アクーゴ
Page 12
12© 2026 CRYOPORT, INC. Cryoport, Inc. Global Locations Irvine, CA Global Logistics Center Houston, TX Global Supply Chain Center Morris Plains, NJ Global Supply Chain Center Amsterdam, NL Global Logistics Center Stevenage, UK Supply Chain Hub Paris, FR Global Supply Chain Center Clermont-Ferrand, FR BioServices Center Pont-du-Château, FR BioServices Center Villers-le-Bouillet, BE Cryopreservation Center Tokyo, Japan Global Logistics Center San Antonio, TX Biostorage Facility New Prague, MN Manufacturing Facility Chengdu, China Manufacturing Facility Ball Ground, GA Manufacturing Facility Tampa, FL Biostorage Facility Coming Soon Nashville, TN Corporate HQ Darmstadt, DE Tec4Med Lifescience Houston, TX Biostorage Facility
Page 13
13© 2026 CRYOPORT, INC.
Page 14
14© 2026 CRYOPORT, INC.
Page 15
15© 2026 CRYOPORT, INC.
Page 16
16© 2026 CRYOPORT, INC.
Page 17
17© 2026 CRYOPORT, INC.
Page 18
18© 2026 CRYOPORT, INC. Driving Bottom-Line Improvement 46.6% $0.4M $397M Gross Margin from Continuing Operations Adjusted EBITDA from Continuing Operations Cash and Short-Term Investment